ERC1

Across TCGA pan-cancer cohorts, ERC1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ERC1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ERC1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ERC1 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

HNSC, COAD, and CCRCC are the cancer types where ERC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.336	<.001	11	view →
COAD	Female	All	−0.312	<.001	9	view →
CCRCC	Male	All	+0.168	<.001	9	view →
LUAD	Female	II,III,IV	−0.251	<.001	7	view →
LSCC	Female	III,IV	−0.197	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ERC1–HNSC

Open the HNSC breakdown →